Real-World Comparison of Esaxerenone with Other Mineralocorticoid Receptor Antagonists (MRAs): Efficacy, Safety, and Clinical Implications

Abstract

Mineralocorticoid receptor antagonists (MRAs) are cornerstone therapies in the management of hypertension, heart failure, and chronic kidney disease. Esaxerenone, a novel selective non-steroidal MRA, has emerged as a promising agent, prompting comparisons with established agents such as spironolactone and eplerenone. This review synthesizes current real-world evidence regarding the efficacy, safety, and clinical utility of esaxerenone relative to other MRAs, highlighting mechanistic distinctions, therapeutic outcomes, and guideline implications for healthcare professionals managing patients with cardiorenal syndromes.

Introduction

MRAs have revolutionized the management of cardiorenal disorders, particularly in patients with resistant hypertension, heart failure with reduced ejection fraction, and chronic kidney disease. Spironolactone and eplerenone, the traditional steroidal MRAs, have well-established efficacy but are limited by adverse effects such as hyperkalemia and endocrine disturbances. Esaxerenone, a next-generation non-steroidal MRA, offers enhanced receptor selectivity and favorable pharmacokinetics. This article provides a comprehensive, evidence-based comparison of esaxerenone and other MRAs, focusing on real-world data, clinical relevance, and practical implications for healthcare professionals.

Epidemiology / Disease Burden

Hypertension and heart failure constitute leading contributors to global morbidity and mortality, with the prevalence of resistant hypertension estimated at 10–20% of hypertensive populations. Cardiorenal syndromes further compound clinical complexity, increasing hospitalization rates and healthcare expenditures. MRAs have demonstrated morbidity and mortality benefits in these populations, yet underutilization persists due to safety concerns, particularly hyperkalemia and renal dysfunction. The emergence of esaxerenone provides an opportunity to address these challenges, potentially improving therapeutic penetration among high-risk cohorts.

Pathophysiology

The mineralocorticoid receptor, predominantly activated by aldosterone, mediates sodium retention, potassium excretion, and tissue fibrosis. Chronic overactivation contributes to vascular inflammation, myocardial remodeling, and progressive renal injury. Traditional MRAs antagonize aldosterone at the receptor level but exhibit off-target activity at androgen and progesterone receptors, accounting for adverse endocrine effects. Esaxerenone, characterized by high selectivity for the mineralocorticoid receptor, offers targeted antagonism, minimizing unintended hormonal interactions and potentially improving tolerability.

Risk Factors

Patients most likely to benefit from MRAs include those with resistant hypertension, heart failure (particularly HFrEF), chronic kidney disease, diabetes, and proteinuria. Risk factors for MRA-related adverse effects encompass advanced age, impaired renal function, concomitant use of renin-angiotensin system inhibitors, and baseline hyperkalemia. Careful patient selection and monitoring are critical to maximizing therapeutic benefit while mitigating risk, especially in real-world settings where comorbidities and polypharmacy predominate.

Clinical Features

Patients eligible for MRA therapy often present with uncontrolled blood pressure, evidence of target organ damage, or persistent proteinuria. In heart failure, clinical features include fluid overload, dyspnea, and reduced exercise tolerance. The presence of diabetes, microalbuminuria, or declining estimated glomerular filtration rate (eGFR) further identifies candidates for MRA initiation. Recognition of these features facilitates timely intervention, potentially altering disease trajectories and improving outcomes.

Diagnosis

Assessment prior to MRA initiation should include thorough evaluation of renal function, electrolyte status, and cardiac parameters. Baseline measurement of serum potassium and eGFR is imperative, with ongoing monitoring to detect early signs of hyperkalemia or renal impairment. In resistant hypertension, exclusion of secondary causes and confirmation of true resistance are essential to ensure appropriate patient selection for MRA therapy.

Treatment & Management

Spironolactone has long been the MRA of choice for resistant hypertension but is frequently limited by gynecomastia, menstrual irregularities, and impotence due to its non-selective steroidal structure. Eplerenone, with greater receptor selectivity, reduces endocrine side effects but is less potent and more costly. Esaxerenone, as demonstrated in Japanese real-world studies and clinical trials, effectively lowers blood pressure and proteinuria, with a safety profile comparable or superior to steroidal MRAs. Dose titration and individualized therapy based on renal function and potassium levels remain central to successful management.

Recent Advances / Emerging Therapies

Esaxerenone's development reflects a broader trend towards selective receptor modulation in cardiovascular and renal therapeutics. Recent real-world studies, including the ESAX-HTN and ESAX-DN trials, show sustained reductions in systolic and diastolic blood pressure, as well as albuminuria, in diverse patient populations. Importantly, esaxerenone demonstrates a lower incidence of hyperkalemia compared to spironolactone, even among patients with moderate renal impairment. Ongoing research explores its utility in heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy, expanding its potential indications.

Guideline Recommendations

Guidelines from the American College of Cardiology, American Heart Association, and Japanese Society of Hypertension recognize MRAs as essential in resistant hypertension and heart failure. While spironolactone remains the first-line agent, eplerenone and esaxerenone are recommended alternatives, particularly in patients experiencing intolerable side effects or at higher risk of endocrine complications. The 2022 Japanese guidelines endorse esaxerenone for hypertension and diabetic nephropathy, citing its superior selectivity and tolerability. International harmonization of recommendations is anticipated as further real-world and randomized evidence accumulates.

Conclusion

Esaxerenone represents a significant advance in MRA therapy, offering a favorable balance of efficacy and safety relative to traditional steroidal agents. Real-world data reinforce its utility in lowering blood pressure and albuminuria with reduced risk of endocrine adverse effects and hyperkalemia. Careful patient selection, vigilant monitoring, and adherence to evolving guideline recommendations are essential to optimizing outcomes. As ongoing studies clarify its role in broader cardiorenal syndromes, esaxerenone is poised to become an integral component of evidence-based management for high-risk cardiovascular and renal populations.